The companies plan to request emergency use authorization from the US Food and Drug Administration for a booster dose for this age group. The new data come from a small study of 140 children ages 5 through 11 who were given a third 10-microgram dose of the Pfizer-BioNTech Covid-19 vaccine at least six months after their second dose. The companies said there were no safety issues associated with a booster dose of the vaccine in these small groups of children. The primary series of two doses was authorized by the FDA for emergency use in this age group in October. Booster doses of Pfizer’s Covid-19 vaccine are already authorized for people age 12 and older.

Source: CNN April 15, 2022 14:43 UTC